Tagworks: using click chemistry to make ADCs more applicable and radiotherapies safer

Netherlands-based Tagworks is using click chemistry to simultaneously accomplish on-target activation of ADCs and off-target deactivation of radiopharmaceuticals. After spinning out of Philips Healthcare in 2011, the company has announced a $65 million series A round co-led by Ysios Capital and Gilde Healthcare. 

Tagworks Pharmaceuticals B.V. CEO Marc Robillard told BioCentury that antibody-drug conjugates (ADCs) are limited by a paucity of receptors that are selectively over expressed on cancer cells and capable of internalizing the ADC into the cell...